MAY 01, 2018 01:36 PM PDT

Ditching Mammograms for Dye-Based Breast Cancer Diagnosis

WRITTEN BY: Kara Marker

Move over, mammograms. University of Michigan scientists have a new solution for diagnosing breast cancer that’s possibly more accurate, less invasive, and less uncomfortable. With a pill that delivers a dye to illuminate tumors under infrared light, determining the difference between benign and malignant could become easier than ever before.

Tumors are targeted by a molecule that carries a fluorescent imaging agent in order to make earlier and more accurate breast cancer diagnoses. Credit: Evan Dougherty/Michigan Engineering Communications & Marketing

Many women undergo unnecessary diagnostic tests only to find that their tumor is harmless. The new technology might improve the chances that invasive approaches like surgery and chemotherapy can be reserved for malignant tumors that require this step. Additionally, scientists want to limit the malignant tumors that go unnoticed because thick breast tissue hides lumps. And of course, limiting the number of unnecessary tests will help avoid unnecessary costs.

"We overspend $4 billion per year on the diagnosis and treatment of cancers that women would never die from," explained study leader Greg Thurber, PhD.

The new diagnostic method provides an alternative to mammography, which is uncomfortable for many women and which experts from the study say is imprecise. Mammography provides an x-ray image of the breast, obtained by flattening the breast against the mammogram machine.

University of Michigan researchers, led by Thurber, developed a pill, taken orally by the patient being tested, that delivers a dye responding to infrared light. The dye tags a molecule commonly found on tumor cells and in the surrounding environment. The information obtained from this test can answer the most important question: benign or malignant?

While developing the new diagnostic system, researchers came across issues with creating a pill to carry the dye to the tumor.

"To get a molecule absorbed into the bloodstream, it needs to be small and greasy,” Thurber explained. “But an imaging agent needs to be larger and water-soluble. So you need exact opposite properties.”

They found their solution in a targeting molecule originally designed by Merck for treating cancer. While the molecule didn’t work for their purposes, it did work for the University of Michigan scientists. With this targeting molecule incorporated, the pill can successfully travel through the stomach to the liver and into the bloodstream.

For now, researchers have only shown the diagnostic method to be effective and safe in mice, but further studies are definitely on the horizon.

The present study was published in the journal Molecular Pharmaceutics.

Sources: American Cancer Society, University of Michigan

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 24, 2018
Cancer
APR 24, 2018
CAR-T Cell Therapy 101
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a useful tool for cancer treatments in a small number of cancers thus far. This area of treatment research is expanding rapidl...
MAY 10, 2018
Immunology
MAY 10, 2018
New Biomarker for Lung Cancer Diagnosis
Lung cancer is the most common cause of death from cancer for both genders and for people all over the globe. This is largely due to the lack of diagnostic...
JUN 08, 2018
Clinical & Molecular DX
JUN 08, 2018
Early Detection of Tooth Decay from Bacterial Invasion
We all get cavities, but have we ever thought much about the biology of the process? From the Akson Russian Science Communication Association, scientists i...
JUN 16, 2018
Clinical & Molecular DX
JUN 16, 2018
Nanoparticles Deliver "Theranostics" for Cancer Patients
New technology combing therapeutic agents and diagnostics (theranostics) can be used to deliver drugs to cancer cells. From the Moscow Institute of Physics...
AUG 22, 2018
Clinical & Molecular DX
AUG 22, 2018
Biomarker Predicts Kidney Cancer
A research study led by Beth Israel Deaconess Medical Center has discovered a tumor biomarker that could be used to determine the onset of renal cell carci...
SEP 29, 2018
Microbiology
SEP 29, 2018
In a First, Rat Variation of Hepatitis E Found in a Person
It was found in a 56-year-old Hong Kong man....
Loading Comments...